Tag Archives: Kevin Degeeter

Oppenheimer Keeps Their Hold Rating on Personalis (PSNL)

Oppenheimer analyst Kevin DeGeeter maintained a Hold rating on Personalis (PSNL – Research Report) today. The company’s shares closed last Tuesday at $23.40. According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 46.5% and a 49.3%

Oppenheimer Issues a Buy Rating on BioNano Genomics (BNGO)

Oppenheimer analyst Kevin DeGeeter assigned a Buy rating to BioNano Genomics (BNGO – Research Report) today and set a price target of $15.00. The company’s shares closed last Tuesday at $8.37. According to TipRanks.com, DeGeeter is a top 100 analyst

Analysts Offer Insights on Healthcare Companies: DermTech (NASDAQ: DMTK) and Kadmon Holdings (NASDAQ: KDMN)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on DermTech (DMTK – Research Report) and Kadmon Holdings (KDMN – Research Report) with bullish sentiments. DermTech (DMTK) Oppenheimer analyst Kevin DeGeeter maintained

Personalis (PSNL) Receives a Rating Update from a Top Analyst

In a report released today, Kevin DeGeeter from Oppenheimer maintained a Hold rating on Personalis (PSNL – Research Report). The company’s shares closed last Monday at $37.93. According to TipRanks.com, DeGeeter is a top 100 analyst with an average return

What Made Oppenheimer Downgrade Personalis’ Stock?

Personalis (PSNL – Research Report) received a Hold rating from Oppenheimer analyst Kevin DeGeeter today. The company’s shares closed last Thursday at $26.77, close to its 52-week high of $30.95. According to TipRanks.com, DeGeeter is a 5-star analyst with an

Fulgent Genetics (FLGT) Receives a Buy from Oppenheimer

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Fulgent Genetics (FLGT – Research Report) today and set a price target of $75.00. The company’s shares closed last Friday at $32.53. According to TipRanks.com, DeGeeter is a 5-star analyst with